Richard Bhatt
MD
Medical Oncologist
👥Biography 个人简介
Richard Bhatt has contributed to clinical development of metabolic inhibitors in oncology, including CB-839 (telaglenastat), a glutaminase inhibitor that targets cancer's glutamine dependence. His clinical trial work investigating glutaminase inhibition in combination with other agents in renal cell carcinoma and other tumor types has contributed to defining the clinical utility and limitations of metabolic targeting in cancer treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Richard Bhatt 的研究动态
Follow Richard Bhatt's research updates
留下邮箱，当我们发布与 Richard Bhatt（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment